Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan

Accesswire June 29, 2022

Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis

Accesswire June 27, 2022

Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19

Accesswire June 23, 2022

Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo

Accesswire June 13, 2022

Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements

Accesswire June 9, 2022

Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray

Accesswire June 8, 2022

Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia

Accesswire May 31, 2022

Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray

Accesswire May 23, 2022

Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study

Accesswire May 20, 2022

Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference

Accesswire May 19, 2022

Altamira Therapeutics Issues Shareholder Letter

Accesswire May 18, 2022

Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia

Accesswire May 5, 2022

Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19

Accesswire April 19, 2022

Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results

Accesswire April 12, 2022

Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant

Accesswire April 11, 2022

Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET

Accesswire April 4, 2022

Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio

Accesswire March 15, 2022

Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant

Accesswire March 11, 2022

Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19

Accesswire March 9, 2022

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets

Accesswire March 4, 2022